Post-radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: one centre experience and review of published works

Australas Radiol. 2007 Dec;51(6):550-4. doi: 10.1111/j.1440-1673.2007.01871.x.

Abstract

The aim of this study was to evaluate prospectively post-radiofrequency ablation (RFA) syndrome and to determine its effect on the quality of life in the 15 days after percutaneous RFA treatment. We carried out an internal review board-approved prospective study of the delayed symptoms that occurred after 71 consecutive RFA sessions in 53 patients (12 women and 41 men; age range 45-83 years; mean age 71.6 years) with 45 primary liver tumours, 34 liver metastases, 3 renal cell carcinoma (RCC), 2 residual lesions from RCC after nephrectomy and 1 pancreatic metastases from RCC. Postablation symptoms occurred in 17 of 53 (32%) patients. Six of 17 patients developed low-grade fever (from 37.5 to 38.5 degrees C). Other symptoms included delayed pain (9/17), nausea (7/17), vomiting (3/17), malaise (3/17) and myalgia (1). Postablation syndrome is a common phenomenon after RFA of solid abdominal tumours. Not only in our study but also in the previous ones the occurrence is observed in approximately one-third patients. Patients should be informed that these symptoms are self-limiting after RFA and most patients should be able to resume near-complete preprocedural levels of activity within 10 days after the procedure.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / surgery
  • Catheter Ablation / adverse effects*
  • Chi-Square Distribution
  • Female
  • Humans
  • Kidney Neoplasms / surgery*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Male
  • Middle Aged
  • Neoplasm, Residual / surgery
  • Pancreatic Neoplasms / secondary
  • Pancreatic Neoplasms / surgery*
  • Prospective Studies
  • Radiography, Interventional*
  • Syndrome